Methotrexate for the treatment of refractory Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 3, 1996, Pages 309-314

  Lemann M ^a   Chamiot Prieur, C ^a   Mesnard, B ^b   Halphen, M ^c   Messing, B ^c   Rambaud, J C ^c   Gendre, J P ^d   Colombel, J F ^b   Modigliani, R ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Hopital Saint Lazare   (France)

^d HÔPITAL ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0030004052     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0953-0673.1996.00309.x     Document Type: Article

References (15)

1. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
2. Kozarek RA, Patterson DJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease. Gastroenterology 1992; 102: A648.
3. Kozarek RA, Patterson DJ, Botoman VA, Ball TJ, Gelfand MD. Methotrexate use in inflammatory bowel disease patients who have failed azathioprine or 6-mercaptopurine. Gastroenterology 1991; 100: A222.
4. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6.
5. Arora S, Katkov WN, Cooley J, et al. A double-blind, randomized, placebo-controlled trial of methotrexate of Crohn's disease. Gastroenterology 1992; 102: A591.
6. Feagan B, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
7. Bernades P, Hecketsweiler P, Benozio M, et al. Proposition d'un système de critères pour le diagnostic des entérocolites inflammatoires et cryptogénétiques (maladie de Crohn et rectocolite hémorragique): une étude coopérative du GREC. Gastroenterol Clin Biol 1978; 52: 1047-54.
8. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980: i: 514.
9. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
10. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 39-46.
11. Kaplan LE, Meier P. Non parametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81.
12. O'Donoghue DP, Dawson AM, Powel-Tuck K, Bown RL. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; ii: 944-6.
13. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 547: 215-9.
14. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff A. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198-205.
15. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 9-18.